Safeguard Scientifics has a unique and consistent approach to putting capital to work in the life sciences sector. We target capital efficient diagnostic companies that we believe will have success with applications they submit to the FDA. In addition,...

PixelOptics’ emPower! eyewear is the world’s first and only electronic focusing eyeglasses—focusing faster than the blink of an eye. The technology is embedded inside the lenses and powered by tiny microelectronics hidden inside the frames, providing...

Ninety percent of migraine sufferers experience nausea, while 60 percent experience vomiting because of their migraine. As a result, today’s most common migraine treatments that are administered orally are less effective. Enter Zelrix, or NP101, which...

According to a report published by Cambridge Associates LLC, private equity and venture capital funds in the U.S. continued to generate positive returns for their investors during the second quarter. The funds also finished the first half of 2011 with...

As Peter J. Boni highlighted this morning, despite volatile capital markets and a wobbly economy, Safeguard Scientifics continues to fire on all cylinders by realizing value through well-timed exit transactions and deploying capital in new growth opportunities. For...

The IPO Task Force unveiled a new effort to ease the IPO road for emerging companies in its report, “Rebuilding the IPO On-Ramp.” The report calls for an easing of regulations that it says are holding back emerging U.S. companies. Among its recommendations,...